Johnson & Johnson seen reporting strong quarterly revenue growth

Shares of Johnson & Johnson JNJ.N rise 1.9% to $252.77 ahead of its quarterly earnings report due before markets open on Wednesday.

** Wall Street analysts expect JNJ to report ~3% growth in adjusted EPS to $2.85; revenue is seen growing 5.50% to $25 bln.

** JNJ's revenue and adjusted EPS have met or exceeded analyst expectations every time in the last 8 quarters.

** JNJ's medical device subsidiary Abiomed won a jury trial in Massachusetts over allegations that it violated Maquet Cardiovascular's patent rights in heart-pump technology.

** Among 27 analysts that cover JNJ, average rating is "BUY" and median PT is $264, per LSEG data.

** JNJ is up 22.3% YTD vs S&P 500 health index .SPXHC, which is up 2.25% in the same period.